主讲人：史册助理教授（香港中文大学经济系）

主持人：侯尚迪助理教授（辽宁大学中国经济研究院）

嘉宾介绍：马湘君教授（辽宁大学中国经济研究院）

时间：2024年4月24日（周三）  9：00-10：30（北京时间）

地点：辽宁大学崇山校区五洲园一楼会议室

线上地址：腾讯会议：422-670-019

语言：中文/英文

摘要：This paper investigates the impact of public health insurance on pharmaceutical development in China. While extensive evidence from developed countries indicates a positive relationship between market size and pharmaceutical innovation, it remains unclear whether and how policy-induced market incentives affect pharmaceutical research and development (R&D) in developing countries. Using novel data on clinical trials and marketing applications for new drugs in China from 2007 to 2020, we measure pharmaceutical innovation and imitation separately. By exploiting the quasi-experimental setting of a large-scale public insurance program for catastrophic diseases in China---the Critical Illness Insurance Program (CII)---we find that the number of new clinical trials for the affected diseases did not increase in response to the policy change. However, the CII is associated with a significant increase in new generic drug marketing applications. Moreover, the increase in generic drug applications is driven by an increase in duplicative generic and chemical drugs rather than first-in-China and biologic drugs requiring relatively higher technology capacities. Our findings underscore the importance of the relationship between imitation and innovation in understanding policy-induced incentives for pharmaceutical R&D in developing countries.

主讲人简介：史册，香港中文大学经济系助理教授，弗吉尼亚大学经济学博士，浙江大学—香港中文大学数字经济联合研究中心副主任。主要研究领域为产业组织与应用微观经济学，研究主题包括数字经济、平台企业与广告、医药产业的实证分析。主持3项香港研资局基金一般项目及青年项目，研究成果发表于Journal of Development Economics等期刊。曾获2019年中国法经济学论坛最佳论文奖、2022年度数字经济研究先锋奖。